Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 15/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 14/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.59 |
| ▸ | QPCT | Q16769 | 1/20 | 0.59 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.59 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9067044 | 0.97 | CYP11B1 (0.94) | CYP11B1CYP11B2CYP17A1CYP19A1POLB | |
| SCHEMBL5545363 | 0.88 | CYP11B1 (0.78) | CYP11B1CYP11B2CYP17A1CYP19A1POLB | |
| SCHEMBL30523908 | 0.84 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP17A1CYP19A1POLB | |
| SCHEMBL15179016 | 0.84 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP17A1CYP19A1POLB | |
| SCHEMBL30523909 | 0.84 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP17A1CYP19A1POLB | |
| SCHEMBL26613644 | 0.82 | CYP11B1 (0.69) | CYP11B1CYP11B2CYP17A1CYP19A1POLB | |
| SCHEMBL6868756 | 0.82 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP17A1CYP19A1POLB | |
| SCHEMBL28781813 | 0.82 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP17A1CYP19A1POLB | |
| SCHEMBL20622756 | 0.79 | CYP11B1 (0.66) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 | |
| SCHEMBL27824075 | 0.79 | CYP19A1 (0.65) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848654-A | Zinc complex with property of catalyzing photo-degradation of methyl orange dye and preparation method thereof | 盐城师范学院 | 2020-10-30 | — | — | CN | claimed |
| EP-1904186-B1 | STABLE SUNSCREEN COMPOSITIONS CONTAINING ZINC OXIDE | AMCOL INTERNATIONAL CORP (US) | 2009-11-04 | — | — | EP | claimed |
| EP-1324017-B1 | Method to determine realistic UV protection factors or broad spectrum indexes | COTY BV (NL) | 2004-10-27 | — | — | EP | claimed |
| EP-3365819-B1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIV OF TECHNOLOGY (ZA) | 2023-06-07 | — | — | EP | disclosed |
| EP-3365330-B1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIV OF TECHNOLOGY (ZA) | 2023-06-07 | — | — | EP | disclosed |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2023-01-10 | — | — | US | disclosed |
| CN-108701171-B | Pharmacophores, compounds and methods having application in the treatment of cancer by inhibition of CYP17a1 and CYP19a1 | 马古苏托科技大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-108779085-B | Pharmacophores, compounds and methods having application in the treatment of cancer by inhibition of CYP17a1 and CYP19a1 | 马古苏托科技大学 | 2022-03-22 | — | — | CN | disclosed |
| EP-3778693-A1 | CURABLE RESIN COMPOSITION, ADHESIVE AGENT, ADHESIVE FILM, CIRCUIT SUBSTRATE, INTERLAYER INSULATING MATERIAL, AND PRINTED WIRING BOARD | Sekisui Chemical Co., Ltd. (JP) | 2021-02-17 | — | — | EP | disclosed |
| CN-111848654-A | Zinc complex with property of catalyzing photo-degradation of methyl orange dye and preparation method thereof | 盐城师范学院 | 2020-10-30 | — | — | CN | disclosed |
| CN-111848654-A | Zinc complex with property of catalyzing photo-degradation of methyl orange dye and preparation method thereof | 盐城师范学院 | 2020-10-30 | — | — | CN | disclosed |
| EP-1227086-A1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-1082289-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1082289-A4 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999066944-A9 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999066944-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0646005-A4 | METHODS FOR TREATING ARTERIOSCLEROSIS. | HARVARD COLLEGE (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0646005-A1 | METHODS FOR TREATING ARTERIOSCLEROSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1995-04-05 | — | — | EP | disclosed |
| WO-1994018968-A1 | METHODS FOR TREATING ARTERIOSCLEROSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1994-09-01 | — | — | WO | disclosed |
| US-5192758-A | Antibiotics | MERCK & CO., INC. (US) | 1993-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | CYP11B1 16/4885CYP11B2 32/4885CYP17A1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.